Medical Cannabis Amendments
SB 64 makes a broad set of revisions to Utah’s medical cannabis regulatory framework. It shifts several licensing and renewal functions from the Department of Agriculture and Food to the Cannabis Production Establishment and Pharmacy Licensing Advisory Board, allows renewals to occur as needed rather than only in December, and updates licensing rules for cannabis cultivation, processing, pharmacies, and couriers. The bill also authorizes a second operating location in limited circumstances for certain processing facilities, limits the number of processing licenses the department may issue, and adds or revises reporting, ownership-change, and background-check requirements across the program.
The bill also changes patient-facing and provider-facing rules. It allows cardholders to use their own opaque bag or box when transporting medical cannabis, removes some information from medical cannabis cards, requires privacy training for certain proxy employees, aligns continuing education requirements for qualified medical providers and pharmacy medical providers, and authorizes patient product information inserts. It further updates surveillance requirements, advertising restrictions, and the rules governing medical cannabis pharmacies, couriers, and recommendation practices near pharmacies.
SB 64 amends numerous sections of Utah Code in Titles 4, 26B, and related repeal provisions, affecting the licensing, operation, oversight, and enforcement of the state medical cannabis program. It repeals the Division of Finance’s role in validating financial institutions for inventory-system access, repeals provisions related to payment providers and a prior enforcement section, and moves or clarifies oversight responsibilities among the Department of Agriculture and Food, the Department of Health and Human Services, and the licensing board. The bill also accelerates the repeal date for the Cannabis Research Review Board and extends the repeal date for the Medical Cannabis Governance Structure Working Group, while adding a coordination clause to align criminal code cross-references.
The overall sentiment appears broadly supportive and pragmatic. The bill advanced with strong committee support in both chambers and passed the House unanimously, while the Senate passed it with comfortable margins despite some dissent on floor votes. The vote pattern suggests legislators generally viewed the measure as a routine but substantial cleanup and modernization of the medical cannabis regulatory scheme rather than a controversial policy shift.
The main points of contention appear to center on regulatory control, market structure, and enforcement. The bill tightens and reorganizes licensing authority, limits certain license counts, and preserves restrictions on ownership and vertical integration, which may draw concern from industry participants seeking more flexibility. It also continues to regulate advertising, proximity to community locations, and anticompetitive conduct, reflecting legislative concern about market concentration and patient access. The repeal of the Division of Finance’s role and the removal of the payment-provider framework suggest a move away from prior financial-access mechanisms, but the available record does not show detailed committee debate on those changes.